Get the Stockscreener App
105.56
0.10%
0.11
Verona Pharma Plc Adr stock is traded at $105.56, with a volume of 974.67K.
It is up +0.10% in the last 24 hours and up +0.52% over the past month.
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
See More
Previous Close:
$105.45
Open:
$105.42
24h Volume:
974.67K
Relative Volume:
0.30
Market Cap:
$8.99B
Revenue:
-
Net Income/Loss:
$-153.72M
P/E Ratio:
-52.78
EPS:
-2
Net Cash Flow:
$-103.81M
1W Performance:
+0.28%
1M Performance:
+0.52%
6M Performance:
+55.33%
1Y Performance:
+290.24%
1-Day Range:
$105.40
$105.67
1-Week Range:
$105.23
$105.85
52-Week Range:
$24.50
$105.85
Verona Pharma Plc Adr Stock (VRNA) Company Profile
Name
Verona Pharma Plc Adr
Sector
Industry
Phone
011-44-0-2032834200
Address
3 MORE LONDON RIVERSIDE, LONDON
Compare VRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRNA
Verona Pharma Plc Adr
|
105.56 | 9.12B | 0 | -153.72M | -103.81M | -2.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-01-25 | Initiated | Wolfe Research | Outperform |
| Apr-28-25 | Initiated | TD Cowen | Buy |
| Apr-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Oct-03-24 | Initiated | Wells Fargo | Overweight |
| May-22-23 | Resumed | Jefferies | Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-26-22 | Initiated | Piper Sandler | Overweight |
| Sep-13-21 | Initiated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Jefferies | Buy |
| Aug-10-20 | Initiated | Canaccord Genuity | Buy |
| Apr-18-19 | Initiated | BTIG Research | Buy |
View All
Verona Pharma Plc Adr Stock (VRNA) Latest News
Verona Pharma (VRNA) Skyrockets 20.6% on $10-Billion Merger Deal with Merck - MSN
Verona Pharma : Notice of Meetings and Proxy Statement in connection with proposed acquisition of Verona Pharma - MarketScreener
Verona Pharma stock reaches all-time high at 105.54 USD By Investing.com - Investing.com Nigeria
Verona Pharma stock reaches all-time high at 105.54 USD - Investing.com
Merck to Acquire Verona Pharma in $10 Billion Deal to Expand Respiratory Drug Portfolio - MSN
Verona Pharma ADR earnings beat by $0.11, revenue topped estimates - Investing.com Nigeria
Verona Pharma CFO Hahn sells $2.75 million in shares By Investing.com - Investing.com India
Verona Pharma (VRNA) director Ackermann sells $24k in shares - Investing.com
Verona Pharma CFO Hahn sells $2.75 million in shares - Investing.com
Verona Pharma director Cunningham sells shares for $142,057 By Investing.com - Investing.com South Africa
Verona Pharma (VRNA) director Deschamps sells $124,391 in shares - Investing.com India
Verona Pharma director Cunningham sells shares for $142,057 - Investing.com India
VERONA PHARMA PLCADR: Quantitative Momentum Investor Model Ratings - AInvest
Global Chronic Obstructive Pulmonary Disease Treatment Devices Market to Witness Growth at a CAGR of ~6% by 2032 | DelveInsight - GlobeNewswire Inc.
Verona Pharma stock hits all-time high at 105.31 USD By Investing.com - Investing.com Nigeria
Verona Pharma stock hits all-time high at 105.31 USD - Investing.com
Verona Pharma Plc ADR’s Shares Reel: 69.24% Quarterly Revenue Decline Amid 8.93B Market Cap - investchronicle.com
Verona Pharma stock reaches all-time high at 105.0 USD By Investing.com - Investing.com Australia
Verona Pharma stock reaches all-time high at 105.0 USD - Investing.com
Pharmaceutical Stocks To Research – July 12th - Defense World
Top Medical Stocks To Follow Now – July 12th - Defense World
Wells Fargo Downgrades Verona Pharma plcDepositary Receipt () (VRNA) - MSN
Merck stock rises as UBS reiterates Buy rating after Verona Pharma acquisition By Investing.com - Investing.com South Africa
Merck to acquire Verona Pharma stock for $107 per ADS in $10 billion deal By Investing.com - Investing.com South Africa
Verona Pharma stock rating downgraded to Neutral by Roth/MKM after Merck offer - Investing.com South Africa
Merck to Acquire Verona Pharma for $10 Billion in Bid to Cushion "Patent Cliff" Impact - Mitrade
Verona Pharma stock hits all-time high at 104.83 USD By Investing.com - Investing.com South Africa
American pharmaceutical company Merck acquires British Verona Pharma for $10 billion - AKM.RU
Verona Pharma stock hits all-time high at 104.83 USD - Investing.com
Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck - Nasdaq
Merck to acquire Verona Pharma for $10 billion By Investing.com - Investing.com Nigeria
Merck dives into COPD treatments with $10 billion purchase of Verona Pharma - MarketWatch
Merck to acquire Verona Pharma for $10 billion - Investing.com Australia
Can Verona Pharma Plc ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Starbucks, Freeport-McMoran and Verona Pharma rise premarket; WPP, T-Mobile fall By Investing.com - Investing.com South Africa
Merck compra por 10.000 millones de dólares Verona Pharma - Yahoo Finanzas
Best Momentum Stock To Buy For July 7th - Barchart.com
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli - Yahoo Finance
Up 515%, Watch This Biopharma Breakout - inkl
Verona Pharma: A Blockbuster Franchise In The Making - Seeking Alpha
Investing $15,000 Into Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth $1 Million Today - Barchart.com
Piper Sandler reiterates Verona Pharma stock rating and target By Investing.com - Investing.com UK
21 Best-Performing Small-Cap Stocks for June 2025 - NerdWallet
Verona Pharma (VRNA) Shares Soar 5.47% to Record High - AInvest
Verona Pharma ADR Surges, Matches Key 52-Week High: What’s Fueling the Rally? - Daily Chhattisgarh News
Verona Pharma stock soars to all-time high of $77.08 By Investing.com - Investing.com Nigeria
FDA Approves GSK's Nucala for Expanded Use in COPD - Zacks Investment Research
Verona Pharma Plc Adr Stock (VRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Verona Pharma Plc Adr Stock (VRNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cunningham Kenneth | Director |
Aug 01 '25 |
Sale |
13.14 |
10,808 |
142,057 |
79,776 |
| Deschamps Lisa | Director |
Aug 01 '25 |
Option Exercise |
0.00 |
24,000 |
0 |
94,320 |
| Deschamps Lisa | Director |
Aug 01 '25 |
Sale |
13.14 |
9,464 |
124,392 |
84,856 |
| Fisher Andrew | General Counsel |
Aug 01 '25 |
Option Exercise |
0.00 |
20,888 |
0 |
427,487 |
| Fisher Andrew | General Counsel |
Aug 01 '25 |
Sale |
13.14 |
9,584 |
125,969 |
417,903 |
| Hahn Mark W | Chief Financial Officer |
Aug 01 '25 |
Option Exercise |
0.00 |
255,696 |
0 |
12,673,880 |
| Hahn Mark W | Chief Financial Officer |
Aug 01 '25 |
Sale |
13.14 |
208,912 |
2,745,877 |
12,464,968 |
| Rickard Kathleen A. | Chief Medical Officer |
Aug 01 '25 |
Option Exercise |
0.00 |
70,888 |
0 |
2,665,808 |
| Rickard Kathleen A. | Chief Medical Officer |
Aug 01 '25 |
Sale |
13.14 |
58,336 |
766,751 |
2,607,472 |
| ACKERMANN CHRISTINA | Director |
Aug 01 '25 |
Option Exercise |
0.00 |
24,000 |
0 |
65,880 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):